<DOC>
	<DOCNO>NCT02592785</DOCNO>
	<brief_summary>Primary objective study assess safety tolerability BAY 1163877 Japanese subject refractory , locally advanced metastatic solid tumor characterize PK BAY 1163877</brief_summary>
	<brief_title>Phase I Dose Escalation Study BAY 1163877 Japanese Subjects With Refractory , Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Japanese male female age ≥ 20 year Histologically cytologically confirm refractory , locally advanced metastatic solid tumor candidate standard therapy discretion investigator High FGFR expression level base archival fresh tumor biopsy specimen analysis . Bladder cancer subject low overall FGFR expression level include activate FGFR3 mutation confirm . Subjects must least one measurable evaluable lesion accord Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST v1.1 ) . Life expectancy least 3 month Recovery National Cancer Institute 's Common Terminology Criteria Adverse Events , version 4.03 ( CTCAE v4.03 ) Grade &lt; 2 level recovery baseline precede prior treatment previous drug / procedurerelated toxicity ( subject persistent alopecia , anemia , and/or hypothyroidism include ) Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 Adequate bone marrow , liver renal function Prothrombin timeInternational normalize ratio ( PTINR ) activate partial thromboplastin time ( APTT ) ≤ 1.5 time ULN . Subjects treat anticoagulant , e.g . warfarin heparin , allow participate provide prior evidence underlie abnormality parameter exist History current condition uncontrolled cardiovascular disease include congestive heart failure New York Heart Association ( NYHA ) &gt; Class 2 , unstable angina ( symptoms angina rest ) newonset angina ( within last 3 month ) myocardial infarction within past 6 month cardiac arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) Left ventricular ejection fraction ( LVEF ) &lt; 50 % assessed echocardiography perform Subjects history and/or current evidence endocrine alteration calcium phosphate homeostasis ( e.g . parathyroid disorder , history parathyroidectomy , tumor lysis , tumoral calcinosis ) . Calcium ( Ca ) x ( time ) phosphate ( PO4 ) &lt; 70 mg²/dL² . Current evidence corneal disorder / keratopathy include limited bullous / band keratopathy , corneal abrasion , inflammation / ulceration , keratoconjunctivitis etc . ( confirmed ophthalmologic examination ) . Preexisting cataract exclusion criterion . Moderate severe hepatic impairment ( subject ChildPugh score B C include . ) Known human immunodeficiency virus ( HIV ) infection Subjects active hepatitis B and/or C infection require treatment Anticancer chemotherapy immunotherapy study within 5halflives anticancer chemotherapy immunotherapy start study treatment . Systolic blood pressure ≤ 110 pulse rate ≥ 100/min , diastolic blood pressure ≤ 70 mmHg pulse rate ≥ 100/min Uncontrolled hypertension indicate rest systolic BP ≥160 mmHg diastolic BP ≥100 mmHg screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>